BioCentury
ARTICLE | Finance

Cell therapy play Neogene’s $110M series A marks first investment for Tordjman’s Jeito Capital

Start-up Neogene has ties to Kite veterans Belldegrun, Chang

September 15, 2020 2:13 AM UTC

Jeito Capital has picked T cell therapy start-up Neogene’s $110 million series A round for its first investment, reflecting the French firm’s focus on preclinical European biotechs that stand to benefit from the firm’s in-house operations, clinical development and market access expertise.

Rafaèle Tordjman, a former Sofinnova Partners managing partner, told BioCentury that she has seen a strong deal flow since launching the firm in January with a €200 million ($223 million) fund (see “Tordjman Launches Jeito”). ...